Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The DNA-histone complex, fundamentally organized as the nucleosome, serves as the primary structural unit for packaging eukaryotic DNA into chromatin. It consists of a histone octamer—comprising two copies each of histones H2A, H2B, H3, and H4—around which approximately 147 base pairs of DNA are wrapped [1, 2]. Beyond its structural role, the complex is a dynamic regulator of genomic access, influencing transcription, DNA replication, and repair through epigenetic modifications and chromatin remodeling [3]. In clinical contexts, the stability and modification state of this complex are frequently altered; for instance, oncohistone mutations can drive oncogenesis by disrupting normal gene expression patterns [3]. Furthermore, nucleosomes released into the bloodstream during cell death serve as potent autoantigens in systemic lupus erythematosus and as diagnostic biomarkers in various cancers [4, 7]. Therapeutic agents such as anthracyclines target this complex by intercalating into the DNA, which can trigger the eviction of histones and subsequent cell death in rapidly dividing malignant cells [5]. Platinum-based drugs also interact with this complex by forming DNA adducts that are processed differently depending on their position within the nucleosome [6]. [1] Luger, K., et al. (1997). Nature, 389(6648), 251-260. [2] Kornberg, R. D. (1974). Science, 184(4139), 868-871. [3] Allis, C. D., & Jenuwein, T. (2016). Nature Reviews Genetics, 17(8), 487-500. [4] Rekvig, O. P. (2015). Frontiers in Immunology, 6, 427. [5] Pang, B., et al. (2013). Nature Communications, 4, 1908. [6] Zhu, G., et al. (2012). Nature, 489(7416), 447-451. [7] Volckmar, A. L., et al. (2018). Genes, Chromosomes and Cancer, 57(3), 123-139.
Drugs interact with the DNA-histone complex through DNA intercalation, which can lead to histone eviction and chromatin destabilization, or by forming covalent DNA adducts that impede transcription and replication within the nucleosomal structure.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nucleosome (DNA-histone complex).